Molecularly targeted therapies improve outcome for lung adenocarcinoma patients whose tumors harbor mutant EGFR or translocated ALK, RET or ROS1, with an encouraging response for those with mutated BRAF, MET, NTRK-1 & 2 and ERBB2 [2–5]. The gene discussed is EGFR; the disease is lung adenocarcinoma.